UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 117

Sortiert nach

Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir

Retrovirology, 2018-08, Vol.15 (1), p.56-56, Article 56

2018

Link zum Volltext

Verfügbarkeit prüfen

Evaluating the combination of emtricitabine/ tenofovir alafenamide fumarate to reduce the risk of sexually acquired HIV-1-infection in at-risk adults

Expert opinion on pharmacotherapy, 2021-07, Vol.22 (10), p.1245-1251

Mesplède, Thibault

2021

Link zum Volltext

Verfügbarkeit prüfen

Investigational drugs for the treatment of Zika virus infection: a preclinical and clinical update

Expert opinion on investigational drugs, 2018-12, Vol.27 (12), p.951-962

2018

Link zum Volltext

Verfügbarkeit prüfen

Antimalarial drugs and their metabolites are potent Zika virus inhibitors

Journal of medical virology, 2019-07, Vol.91 (7), p.1182-1190

2019

Link zum Volltext

Verfügbarkeit prüfen

The antimalarial drug amodiaquine possesses anti‐ZIKA virus activities

Journal of medical virology, 2018-05, Vol.90 (5), p.796-802

2018

Link zum Volltext

Verfügbarkeit prüfen

HIV drug resistance against strand transfer integrase inhibitors

Retrovirology, 2017-06, Vol.14 (1), p.36-36, Article 36

2017

Link zum Volltext

Verfügbarkeit prüfen

Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir

Journal of Virology, 2012-03, Vol.86 (5), p.2696-2705

2012

Link zum Volltext

Verfügbarkeit prüfen

Diverse Types of Diterpenoids with an Aromatized C Ring from the Twigs of Podocarpus imbricatus

Journal of natural products (Washington, D.C.), 2020-08, Vol.83 (8), p.2416-2424

2020

Link zum Volltext

Verfügbarkeit prüfen

Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications

Expert opinion on pharmacotherapy, 2019-03, Vol.20 (4), p.385-397

2019

Link zum Volltext

Verfügbarkeit prüfen

Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity

Journal of antimicrobial chemotherapy, 2016-08, Vol.71 (8), p.2083-2088

2016

Link zum Volltext

Verfügbarkeit prüfen

Investigational drugs for HIV: trends, opportunities and key players

Expert opinion on investigational drugs, 2023-02, Vol.32 (2), p.127-139

2023

Link zum Volltext

Verfügbarkeit prüfen

The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and Integration

Antimicrobial agents and chemotherapy, 2023-05, Vol.67 (5), p.e0138622-e0138622

2023

Link zum Volltext

Verfügbarkeit prüfen

Two Cases of Viral Re-suppression After M184V + R263K Selection on Dolutegravir/Lamivudine Without Treatment Modification

Clinical infectious diseases, 2024-01

2024

Link zum Volltext

Verfügbarkeit prüfen

Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase

Journal of virology, 2015-03, Vol.89 (6), p.3163-3175

2015

Link zum Volltext

Verfügbarkeit prüfen

Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence

Viruses, 2015-07, Vol.7 (7), p.3703-3718

2015

Link zum Volltext

Verfügbarkeit prüfen

Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors

Journal of antimicrobial chemotherapy, 2016-07, Vol.71 (7), p.1948-1953

2016

Link zum Volltext

Verfügbarkeit prüfen

Combination therapies currently under investigation in phase I and phase II clinical trials for HIV-1

Expert opinion on investigational drugs, 2020-03, Vol.29 (3), p.273-283

2020

Link zum Volltext

Verfügbarkeit prüfen

Differences among HIV-1 subtypes in drug resistance against integrase inhibitors

Infection, genetics and evolution, 2016-12, Vol.46, p.286-291

2016

Link zum Volltext

Verfügbarkeit prüfen

The latest evidence for possible HIV-1 curative strategies

Drugs in context, 2018, Vol.7, p.212522-212522

2018

Link zum Volltext

Verfügbarkeit prüfen

p53 Degradation Activity, Expression, and Subcellular Localization of E6 Proteins from 29 Human Papillomavirus Genotypes

Journal of Virology, 2012-01, Vol.86 (1), p.94-107

2012

Link zum Volltext

Verfügbarkeit prüfen

JAK-STAT Signaling Pathways and Inhibitors Affect Reversion of Envelope-Mutated HIV-1

Journal of virology, 2017-05, Vol.91 (9)

2017

Link zum Volltext

Verfügbarkeit prüfen

Where are we with injectables against HIV infection and what are the remaining challenges?

Expert review of anti-infective therapy, 2018-02, Vol.16 (2), p.143-152

2018

Link zum Volltext

Verfügbarkeit prüfen

Exploring an alternative explanation for the second phase of viral decay: Infection of short-lived cells in a drug-limited compartment during HAART

PloS one, 2018-07, Vol.13 (7), p.e0198090-e0198090

2018

Link zum Volltext

Verfügbarkeit prüfen

Investigational HIV integrase inhibitors in phase I and phase II clinical trials

Expert opinion on investigational drugs, 2017-11, Vol.26 (11), p.1207-1213

2017

Link zum Volltext

Verfügbarkeit prüfen

Reply to Achieng and Riedel

The Journal of infectious diseases, 2019-01, Vol.219 (1), p.167-169

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 117

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(115)
Mit Volltextzugriff
(114)

Publikationsform

Artikel
(116)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(90)
Life Sciences & Biomedicine
(87)
Humans
(71)
Virology
(41)
Human Immunodeficiency Virus
(36)
Hiv
(35)
Infectious Diseases
(33)
Hiv-1 - Drug Effects
(31)
Microbiology
(31)
Hiv Integrase - Genetics
(30)
Hiv-1 - Genetics
(30)
Heterocyclic Compounds, 3-Ring - Pharmacology
(29)
Drug Resistance, Viral
(28)
Hiv Integrase Inhibitors - Pharmacology
(28)
Pharmacology & Pharmacy
(27)
Hiv Infections - Drug Therapy
(26)
Drug Resistance
(25)
Hiv-1 - Enzymology
(24)
Hiv Infections - Virology
(23)
Mutation
(23)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir

Evaluating the combination of emtricitabine/ tenofovir alafenamide fumarate to reduce the risk of sexually acquired HIV-1-infection in at-risk adults

Investigational drugs for the treatment of Zika virus infection: a preclinical and clinical update

Antimalarial drugs and their metabolites are potent Zika virus inhibitors

The antimalarial drug amodiaquine possesses anti‐ZIKA virus activities

HIV drug resistance against strand transfer integrase inhibitors

Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir

Diverse Types of Diterpenoids with an Aromatized C Ring from the Twigs of Podocarpus imbricatus

Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications

Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity

Investigational drugs for HIV: trends, opportunities and key players

The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and Integration

Two Cases of Viral Re-suppression After M184V + R263K Selection on Dolutegravir/Lamivudine Without Treatment Modification

Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase

Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence

Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors

Combination therapies currently under investigation in phase I and phase II clinical trials for HIV-1

Differences among HIV-1 subtypes in drug resistance against integrase inhibitors

The latest evidence for possible HIV-1 curative strategies

p53 Degradation Activity, Expression, and Subcellular Localization of E6 Proteins from 29 Human Papillomavirus Genotypes

JAK-STAT Signaling Pathways and Inhibitors Affect Reversion of Envelope-Mutated HIV-1

Where are we with injectables against HIV infection and what are the remaining challenges?

Exploring an alternative explanation for the second phase of viral decay: Infection of short-lived cells in a drug-limited compartment during HAART

Investigational HIV integrase inhibitors in phase I and phase II clinical trials

Reply to Achieng and Riedel

Suchergebnisse filtern